HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Firms Making Drug Claims Land On Fast Track To Notoriety At FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is compiling an ongoing list of “online advisory letters” to identify supplement firms that fail to respond within 30 days to notices about noncompliant claims. The agency anticipates spurring an uptick in NDI notifications by publishing a draft guidance by the end of the year.

You may also be interested in...



Supplement NDI Draft Guidance Discussions Snagged On Basic Criteria

FDA’s dietary supplement division is concerned that firms are not submitting NDI notifications in cases where they should be, while industry stakeholders assert the agency needs to clarify the criteria for determining which products should be the subject of notifications and what information is needed.

New Dietary Ingredient Notification Draft Guidance Must Be Withdrawn – CRN and CHPA

US Proposed OTC Hearing Aid Rule Inspired Soundly Founder To ‘Make This Process Easier’

In recent interview, CEO Blake Cadwell talked about Soundly’s business model and outlook for hearing aid marketplace after FDA's pending publication of rule aiming to make the devices more accessible. Firm since June has offered online testing and advice for customers about hearing aids best suited for their needs.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS123814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel